AI assistant
UCB Major Shareholding Notification 2023
4017_mrq_2023-11-23_e697f244-2e8c-481a-8e3d-2ea023ed2963.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Transparency notification Wellington
Brussels (Belgium), 23 November 2023 – 20:00 (CET) – Regulated information
1. Summary of the notification
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 20 November 2023.
Wellington Management Group LLP has notified that, following a disposal of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has decreased and it has crossed the 7.5% threshold downwards, on 17 November 2023.
On 17 November 2023, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 14 548 260 UCB shares with voting rights, representing 7.48% of the total number of shares issued by the company (194 505 658), versus 7.80% (15 166 845 UCB shares) in the previous notification dated 16 May 2022.
2. Content of the notification
- Reason for the notification: Acquisition or disposal of voting securities or voting rights.
- Notification by: A parent undertaking or a controlling person.
- Persons subject to the notification requirement:
| Name | Address (for legal entities) | |||||
|---|---|---|---|---|---|---|
| Wellington Management Group LLP | 280 Congress Street, Boston, MA, 02210 |
- Date on which the threshold is crossed: 17 November 2023.
- Threshold crossed (in %): 7.5%.
- Denominator: 194 505 658.
0
CALCULATE 14.548.260 7,48%
• Notified details:
| A) Voting rights | Previous notification | After the transaction | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| # of voting rights | # of voting rights | % of voting rights | ||||||||
| Holders of voting rights | Linked to securities | Not linked to the securities |
Linked to securities | Not linked to the securities |
||||||
| Wellington Management Group LLP | 0 | 0 | 0,00% | |||||||
| Wellington Management International Ltd |
1.214.415 | 1.798.313 | 0,92% | |||||||
| Wellington Management Company LLP | 13.952.342 | 12.749.947 | 6,56% | |||||||
| Wellington Management Europe GmbH | 88 | 0 | 0,00% | |||||||
| Subtotal | 15.166.845 | 14.548.260 | 7,48% | |||||||
| TOTAL | 14.548.260 | 0 | 7,48% | 0,00% | ||||||
| B) Equivalent financial instruments | After the transaction | |||||||||
| Holders of equivalent financial instruments |
Type of financial instrument | Expiration date Exercise period or date |
# of voting rights that may be acquired if the instrument is |
% of voting rights | ||||||
| TOTAL | 0 | 0,00% | ||||||||
| TOTAL (A & B) | # of voting rights % of voting rights |
• Chain of controlled undertakings through which the holding is effectively held:
Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.
Wellington Management International Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.
The shares are registered in the names of the Accounts or nominees according to their respective holdings.
• Additional information: Wellington Management Company LLP, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management
companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.
3. Further information
This press release and the detailed transparency notification are available on UCB SA/NV's website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following link.
For further information, contact UCB:
Investor Relations Antje Witte T +32 2 559 94 14 [email protected]
Corporate Communications Laurent Schots T+32 2 559 92 64 [email protected]
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
